Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders

BOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that preclinical data for ORX750, its first orexin agonist development candidate, will be featured in an oral presentation at the World Sleep Congress being held on October 20-25, 2023, in Rio de Janeiro, Brazil. ORX750 is an orally administered, selective orexin receptor 2 (OX2R) agonist in preclinical development for the treatment of narcolepsy and other sleep disorders.

In addition, Sarah Wurts Black, PhD, Head of Biology for Centessa’s orexin program, will co-chair a symposium at the Congress focused on the development of orexin receptor agonists.

“We believe ORX750 has the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders, and we are thrilled with the opportunity to share preclinical data in an oral presentation at the World Sleep Congress,” said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa.

Details of the presentation are as follows:
Title: ORX750, an Oral Selective Orexin Receptor 2 Agonist, Promotes Wakefulness and Reduces Cataplexy in the Orexin/Ataxin-3 Mouse
Link to Abstract: https://ws2023.abstractserver.com/program/#/details/presentations/1347
Ref number: O25
Authors: Sarah Wurts Black, Tod Steinfeld, Karl Gibson, Gregory R. Ott, Emiliangelo Ratti, David Grainger, Mario Alberto Accardi, and Deborah S. Hartman
Oral Presentation: Wednesday, October 25^th at 10:45 AM (local time)

Symposium: Development of hypocretin/orexin receptor agonists: a progress report (Co-chairs Sarah Wurts Black and Thomas S. Kilduff)
Link to Symposium Abstract: https://ws2023.abstractserver.com/program/#/details/sessions/315
Title: Approaches to the discovery and development of hypocretin/orexin receptor agonists
Ref number: S56
Speaker: Sarah Wurts Black
Session details: Tuesday, October 24^th at 3:22 PM (local time)

Additional information about the World Sleep Congress is available at https://worldsleepcongress.com/program. Centessa plans to make its presentation available on the Centessa website at https://investors.centessa.com/events-presentations after the presentations conclude.